Learn about prior authorization for NTI drugs, why insurers require brand names, and how to navigate the process. Discover the risks of delays and new regulations protecting patient access.
Prescribers remain cautious about substituting generic drugs for narrow therapeutic index (NTI) medications like warfarin and levothyroxine due to risks of instability, inconsistent communication, and fragmented state laws-even as generics prove clinically equivalent in most cases.
Switching from brand-name warfarin to a generic version can be safe-but only with careful INR monitoring. Learn why even small changes in formulation matter, how to avoid dangerous bleeding or clotting risks, and what steps to take before and after a switch.
